Bristol Myers Wins FDA Approval of CAR-T for Some Blood Cancers
This article is for subscribers only.
Bristol Myers Squibb Co. won accelerated approval for the first CAR-T therapy for adults with two forms of hard-to-treat leukemia or lymphoma.
The bespoke medicine, Breyanzi, is given as a one-time infusion for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In one trial, 20% of patients experienced a complete response to treatment, after their cancer progressed following at least two rounds of previous therapy.